We serve Chemical Name:tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate CAS:886365-26-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate](https://a.dearchem.com/CAS2/886365-26-0.png)
Chemical Name:tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate
CAS.NO:886365-26-0
Synonyms:(1-[2-amino-1-(4-fluoro-phenyl)-ethyl]-pyrrolidin-3-yl)-carbamic acid tert-butyl ester;3-N-Boc-Amino-1-[2-amino-1-(4-fluoro-phenyl);tert-butyl 1-(2-amino-1-(4-fluorophenyl)ethyl)pyrrolidin-3-ylcarbamate;3-n-boc-amino-1-[2-amino-1-(4-fluoro-phenyl)-ethyl]-pyrrolidine
Molecular Formula:C17H26FN3O2
Molecular Weight:323.40600
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:433.8ºC at 760 mmHg
Density:1.16g/cm3
Index of Refraction:1.549
PSA:67.59000
Exact Mass:323.20100
LogP:3.45360
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (1-[2-amino-1-(4-fluoro-phenyl)-ethyl]-pyrrolidin-3-yl)-carbamic acid tert-butyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-n-boc-amino-1-[2-amino-1-(4-fluoro-phenyl)-ethyl]-pyrrolidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1-[2-amino-1-(4-fluoro-phenyl)-ethyl]-pyrrolidin-3-yl)-carbamic acid tert-butyl ester Use and application,3-N-Boc-Amino-1-[2-amino-1-(4-fluoro-phenyl) technical grade,usp/ep/jp grade.
Related News: AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate manufacturer Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate supplier The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate vendor Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. tert-butyl N-[1-[2-amino-1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]carbamate factory Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.
